MedX Health Corp. Names John Gevisser as Chief Executive Officer

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of John Gevisser as the Company’s Chief Executive Officer, effective immediately.

Mr. Gevisser previously held the position of Chief Digital Officer at Health Partners Group, the United Kingdom’s largest provider of occupational health services, where he led the company’s technology and data strategy. He also oversaw their strategic partnerships and operationalized MedX’s UK pilot programs. Before that, he served as Vice President of Growth & Development at Vitality Group in the United States, where he was responsible for commercializing Vitality’s direct-to-consumer network and managing its global partnership with Apple Health and Apple Watch. Vitality operates the world’s largest wellness platform.

As MedX’s CEO, Gevisser will focus on expanding MedX’s international footprint, advancing the commercialization of its technology platform, and accelerating revenue-generating opportunities.

“John brings deep expertise in digital health and a global perspective that will prove invaluable as we scale MedX’s operations,” said Mike Druhan, MedX President, Dermatology Services. “His ability to execute international growth strategies and navigate an evolving healthcare landscape positions MedX for long-term success.”

“Skin cancer is a largely preventable condition, and employers and insurers are increasingly adopting preventative strategies to reduce the costs of workplace absenteeism,” said John Gevisser. “As a former client, I saw firsthand how seamlessly MedX’s hardware and software delivered peace of mind and fast-tracked access to dermatologists for hundreds of UK employees. This non-invasive technology platform is highly scalable, so the goal is to make this technology available to the at-risk population through occupational healthcare and insurance providers globally. The true strength of MedX lies not only in the speed of its assessments but also in the clinical accuracy of its results. These are exciting times for MedX as its unique solution to at-risk patients in the workplace is gaining market acceptance.”

While passing over the CEO role to Mr. Gevisser, Stephen Lockyer will remain as President of MedX. “The Board and shareholders of MedX are immensely grateful to Stephen, who stepped up as a Director, CEO and President in 2023 and has been a very significant contributor to the development and advances made by the Company since that time,” said Ken McKay, Chairman of the Board.

About MedX Health Corp.

MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy^® technology, integrated into the DermSecure^® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX’s advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy^®, and its secure, cloud-based patient management system, DermSecure^®. SIAscopy^® is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin’s surface. Visit: https://www.medxhealth.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.